Cardioprotective effects of empagliflosin and vildagliptin: clinical and instrumental assessment of structural and functional parameters of the heart and cardiac markers in patients with diabetes type 2
Abstract
This article presents the results of a prospective study of the cardioprotective potential of two groups of hypoglycemic drugs: sodium-glucose cotransporter 2 inhibitors (empagliflozin) and dipeptidyl peptidase 4 (vildaglpitin). 90 patients with type 2 diabetes were randomized using a random number generator into 3 groups, depending on the antihyperglycemic therapy prescribed for the next 6 months: the group that continued to receive gliclazide and metformin, the group in addition to gliclazide and metformin received vildagliptin at a dose of 100 mg/day, the group in addition to gliclazide and metformin received empaglilflozin at a dose of 25 mg/day. Empagliflozin therapy was accompanied by regression of the left ventricular myocardial mass index (118,00 [116,00; 121,00] g/m2 versus 121,00 [118,00; 122,00] g/m2) and a decrease of the natriuretic peptide (proBNP) (23,50 [16,70; 33,30] pg/ml versus 31,00 [24,30; 46,20] pg/ ml (p <0,05).
About the Authors
V. N. Vasilkova
УО «Гомельский государственный медицинский университет»
Russian Federation
Russian Federation
I. Yu. Pchelin
Санкт-Петербургский государственный университет
Russian Federation
Russian Federation
V. K. Bayrasheva
Национальный̆ медицинский исследовательский центр им. В.А. Алмазова
Russian Federation
Russian Federation
Ya. A. Borovets
УО «Гомельский государственный медицинский университет»
Russian Federation
Russian Federation
Yu. I. Yarets
ГУ «РНПЦ радиационной медицины и экологии человека»
Russian Federation
Russian Federation
Ya. L. Navmenova
ГУ «РНПЦ радиационной медицины и экологии человека»
Russian Federation
Russian Federation
E. P. Naumenka
ГУ «РНПЦ радиационной медицины и экологии человека»
Russian Federation
Russian Federation
T. V. Mokhort
УО «Белорусский государственный медицинский университет»
Russian Federation
Russian Federation
References
1. Prevention of cardiovascular disease guided by total risk estimations-challenges and opportunities for practical implementation: highlights of a Cardio-Vascular Clinical Trialists (CVCT) Workshop of the ESC Working Group on CardioVascular Pharmacology and Drug Therapy / F. Zannad [et al.] // Eur. J. Prev. Cardiol. - 2012 - Vol. 19(6). - Р. 1454-1464.
2. Possible mechanisms of direct cardiovascular impact of GLP-1 agonists and DPP4 inhibitors / V. Bistola [et al.] //j. Heart Fail Rev. - 2018. - Vol. 23(3). - P. 377-388.
3. Cardiovascular outcomes in trials of new antidiabetic drug classes: a network meta-analysis / Y. Fei [et al.] // Cardiovasc Diabetol. - 2019. - Vol.18 (1). - P. 112.
4. Deedwania, P. Cardiovascular Protection with Anti-hyperglycemic Agents / P. Deedwania, T. Acharya // Am J Cardiovasc Drugs. - 2019. - Vol. 19(3). - P. 249-257.
5. Dapagliflozin and cardiovascular outcomes in type 2 diabetes / S.D. Wiviott [et al.] // N Engl J Med. - 2019. - Vol. 380. - P. 347-357.
6. Scheen, A.J. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors / A.J. Scheen // Circ Res. - 2018. - Vol. 122(10). - P.1439-1459.
7. Empagliflozin and cardiovascular outcomes in patients with type 2 diabetes and left ventricular hypertrophy: a sub-analysis of the EMPA-REG OUTCOME trial / S. Verma [et al.] // Diabetes Care. - 2019. - Vol. 42. - P. e42-e44.
8. Verma, S. The serendipitous story of SGLT2 inhibitors in heart failure / S. Verma, J.J.V. McMurray // Circulation. - 2019. - Vol. 139. - P. 2537-2541.
9. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes / B. Zinman [et al.] // N Engl J Med. - 2015. - Vol. 373(22). - P. 2117-2128.
10. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis / T. Toyama [et al.] // Diabetes Obes Metab. - 2019. - Vol. 21(5). - P. 1237-1250.
11. Механизмы нейропротективного действия инкретиномиметиков / Т.Д. Власов [и др.] // Кардиология. Сахарный диабет. - 2016. - № 19. - С. 66-23.
12. Ингибиторы дипептидилпептидазы-4 в лечении сахарного диабета 2 типа. Возможности кардиопротекции / E.Н. Трунина [и др.] // Кардиология. Сахарный диабет. - 2011. - № 2. - С. 59-64.
13. Nauck, M.A. Incretin hormones: Their role in health and disease / M.A. Nauck, J.J. Meier // Diabetes Obes Metab. - 2018. - Vol. 20. Suppl 1. - P. 5-21.
14. The protective role of DPP4 inhibitors in atherosclerosis / H. Liu [et al.] // Eur J Pharmacol. - 2020. - Vol. 15. - P. 875:173037.
15. Heme oxygenase-1 regulates mitochondrial quality control in the heart / T.D. Hull [et al.] // Cardiology. - 2016. - Vol. 1(2). - P. 378-383.
16. Assessing the cardio-cerebrovascular safety of vildagliptin: meta-analysis of adjudicated events from a large Phase III type 2 diabetes population / A. Schweizer [et al.] // Diabetes, Obesity and Metabolism. - 2010. - Vol.12. - P. 485-494.
Review
For citations:
Vasilkova V.N., Pchelin I.Yu., Bayrasheva V.K., Borovets Ya.A., Yarets Yu.I., Navmenova Ya.L., Naumenka E.P., Mokhort T.V. Cardioprotective effects of empagliflosin and vildagliptin: clinical and instrumental assessment of structural and functional parameters of the heart and cardiac markers in patients with diabetes type 2. Medical and Biological Problems of Life Activity. 2021;(2):91-98. (In Russ.)
Views: 108
Email this article 